Clinical Trials Browser

Interventional × Breast Carcinoma In Situ × Nivolumab × Clear all

NCT04185311 2023-08-15

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1 Terminated

Breast Carcinoma In Situ, Triple Negative Breast Neoplasms